Safety and efficacy of fluticasone propionate in the topical treatment of skin diseases

Skin Pharmacology and Physiology

Volumn 18, Issue 1, 2005, Pages 3-11

  Roeder, A ^a   Schaller, M ^b   Schafer Korting M ^c   Korting, H C ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Atopic dermatitis; Fluticasone propionate; Psoriasis; Topical corticosteroids; Vitiligo

Indexed keywords

ANTIINFLAMMATORY AGENT; BECLOMETASONE DIPROPIONATE; BETAMETHASONE; BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; BUDESONIDE; CLOBETASOL BUTYRATE; CLOBETASOL PROPIONATE; DEXAMETHASONE; FLUNISOLIDE; FLUOCINOLONE ACETONIDE; FLUTICASONE PROPIONATE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; HYDROCORTISONE BUTYRATE; MOMETASONE FUROATE; PIMECROLIMUS; PREDNICARBATE; TIXOCORTOL PIVALATE; TRIAMCINOLONE ACETONIDE;

ACNE; ATOPIC DERMATITIS; BLEPHARITIS; BLINDNESS; BURN; CATARACT; CLINICAL TRIAL; CONTACT ALLERGY; CONTACT DERMATITIS; CREAM; CUSHING SYNDROME; DELAYED HYPERSENSITIVITY; DIABETES MELLITUS; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; ECZEMA; ELECTROLYTE DISTURBANCE; ERYTHEMA; EYELID; FACE; FOLLICULITIS; GLAUCOMA; GROWTH RETARDATION; HUMAN; HYPERPIGMENTATION; HYPERTENSION; HYPERTRICHOSIS; INTERTRIGO; INTRAOCULAR HYPERTENSION; LIPOPHILICITY; NEURODERMATITIS; OINTMENT; OSTEOPOROSIS; PERIORAL DERMATITIS; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PUSTULE; RECEPTOR BINDING; REVIEW; ROSACEA; SEBORRHEIC DERMATITIS; SKIN ALLERGY; SKIN ATROPHY; SKIN DISEASE; STRENGTH; TELANGIECTASIA; TURNOVER TIME; VITILIGO;

ADMINISTRATION, CUTANEOUS; ANDROSTADIENES; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; HUMANS; PSORIASIS; SKIN DISEASES; VITILIGO;

EID: 11444252863     PISSN: 16605527     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081680     Document Type: Review

References (68)

1. Katz HI: Topical corticosteroids. Dermatol Clin 1995;13:805-815.
2. Spencer CM, Wiseman LR: Topical fluticasone propionate: A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. Biodrugs 1997;7:318-334.
3. Högger P: Comparison of the tissue affinity of glucocorticoids to human lung, nasal, and skin tissue in vitro. Arzneimittelforschung 2001;51:825-831.
4. McLean HM, Khalil MA, Heiman AS, Lee HJ: Novel fluorinated anti-inflammatory steroid with reduced side effects: Methyl-9-alpha- fluoroprednisolone-16-carboxylate. J Pharm Sci 1994;83:476-480.
5. Phillipps GH: Structure-activity relationships of topically active steroids: The selection of fluticasone propionate. Respir Med 1990;84:19-23.
6. Phillipps GH, Bailey EJ, Bain BM, Borella RA, Buckton JB, Clark JC, Doherty AE, English AF, Fazakerley H, Laing SB: Synthesis and structure-activity relationships in a series of anti-inflammatory corticosteroid analogues, halomethyl androstane-17-beta-carbothioates and 17-beta-carboselenoates. J Med Chem 1994;37:3717-3729.
7. Högger P, Rohdewald P: Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids 1994;59:597-602.
8. Harding SM: The human pharmacology of fluticasone propionate. Respir Med 1990;84:25-29.
9. Popper TL, Gentles MJ, Kung TT, Berkenkopf J, Lutsky BN, Watnick AS, Shapiro EL: Structure-activity relationships of a series of novel corticosteroids. J Steroid Biochem 1987;27:837-843.
10. Makarov SS: NF-kappa B as a therapeutic target in chronic inflammation: Recent advances. Mol Med Today 2000;6:441-448.
11. De Bosscher K, Van den Berghe W, Haegeman G: The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: Molecular mechanisms for gene repression. Endocr Rev 2003;24:488-522.
12. Johnson M: Anti-inflammatory properties of fluticasone propionate. Int Arch Allergy Immunol 1995;107:439-440.
13. Atsuta J, Plitt J, Bochner BS, Schleimer RP: Inhibition of VCAM-1 expression in human bronchial epithelial cells by glucocorticoids. Am J Respir Cell Mol Biol 1999;20:643-650.
14. Llewellyn-Jones CG, Hill SL, Stockley RA: Effect of fluticasone propionate on neutrophil chemotaxis, superoxide generation, and extracellular proteolytic activity in vitro. Thorax 1994;49:207-212.
15. Johnson M: The anti-inflammatory profile of fluticasone propionate. Allergy 1995;50:11-14.
16. Zhang X, Moilanen E, Kankaanranta H: Enhancement of human eosinophil apoptosis by fluticasone propionate, budesonide, and beclomethasone. Eur J Pharmacol 2000;406:325-332.
17. Gangemi S, Ruello A, Arena A, Minciullo P, Pirazzoli A, DiBlasi P, Purello-D'Ambrosio F, Alba Merendino R: In vitro effect of fluticasone propionate on interleukin 8 production by monocytes obtained from patients affected by moderate-severe allergic asthma. Pharmacology 2002;66:57-60.
18. Di Lorenzo G, Pacor ML, Pellitteri ME, Gangemi S, DiBlasi P, Candore G, Colombo A, Lio D, Caruso C: In vitro effects of fluticasone propionate on IL-13 production by mitogen-stimulated lymphocytes. Mediators Inflamm 2002;11:187-190.
19. Hagan JB, Kita H, Gleich GJ: Inhibition of interleukin-5 mediated eosinophil viability by fluticasone 17-propionate: Comparison with other glucocorticoids. Clin Exp Allergy 1998;28:999-1006.
20. McKenzie AW, Stoughton RB: Method for comparing percutaneous absorption of steroids. Arch Dermatol 1962;86:608-610.
21. Cornell RC, Stoughton RB: Correlation of the vasoconstriction assay and clinical activity in psoriasis. Arch Dermatol 1985;121:63-67.
22. Preclinical data on file, GlaxoSmithKline GmbH & Co KG, Munich, Germany.
23. Fisher DA: Adverse effects of topical corticosteroid use. West J Med 1995;162:476.
24. Fowler PD, Gazis AG, Page SR, Jones NS: A randomized double-blind study to compare the effects of nasal fluticasone and betamethasone on the hypothalamo-pituitary-adrenal axis and bone turnover in patients with nasal polyposis. Clin Otolaryngol 2002;27:489-493.
25. Li JT, Goldstein MF, Gross GN, Noonan MJ, Weisberg S, Edwards L, Reed KD, Rogenes PR: Effects of fluticasone propionate, triamcinolone acetonide, prednisone, and placebo on the hypothalamic-pituitary-adrenal axis. J Allergy Clin Immunol 1999;103:622-629.
26. Falcoz C, Oliver R, McDowall JE, Ventresca P, Bye A, Daley-Yates PT: Bioavailability of orally administered micronised fluticasone propionate. Clin Pharmacokinet 2000;39:9-15.
27. Szefler SJ: Pharmacokinetics of intranasal corticosteroids. J Allergy Clin Immunol 2001;108:26-31.
28. Young MMR, Sohail S, Harding SM: A comparison of the systemic absorption of fluticasone propionate and betamethasone valerate after topical application of cream formulations. Br J Dermatol 1994;131:35-36.
29. Juhlin L: Comparison of fluticasone propionate cream, 0.05%, and hydrocortisone-17-butyrate cream, 0.1%, in the treatment of eczema. Cutis 1996;57:51-56.
30. Korting HC, Kerscher MJ, Schäfer-Korting M: Topical glucocorticoids with improved benefit/risk ratio: Do they exist? J Am Acad Dermatol 1992;27:87-92.
31. Korting HC: Topical glucocorticoids and thinning of normal skin as to be assessed by ultrasound; in Korting HC, Maibach HI (eds): Topical Glucocorticoids with Increased Benefit/Risk Ratio. Basel, Karger, 1993, pp 114-121.
32. Kolbe L, Kligman AM, Schreiner V, Stoudemayer T: Corticosteroid-induced atrophy and barrier impairment measured by non-invasive methods in human skins. Skin Res Technol 2001;7:73-77.
33. Dykes PJ, Marks R, Hill S, Mills C, Eastwood R: The kinetics of skin thinning induced by topical fluticasone propionate 0.05% cream in volunteer subjects. Clin Exp Dermatol 1996;21:180-184.
34. Tan CY, Marks R, Payne P: Comparison of xeroradiographic and ultrasound detection of corticosteroid induced dermal thinning. J Invest Dermatol 1981;76:126-128.
35. Tharp MD: A comparison of twice-daily and once-daily administration of fluticasone propionate cream, 0.05%, in the treatment of eczema. Cutis 1996;57:19-26.
36. Friedlander SF, Hebert AA, Allen DB, Fluticasone Pediatrics Safety Study Group: Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. J Am Acad Dermatol 2002;46:387-393.
37. Tan MH, Lebwohl M, Esser AC, Wei H: The penetration of 0.005% fluticasone propionate ointment in eyelid skin. J Am Acad Dermatol 2001;45:392-396.
38. English JS: Corticosteroid-induced contact dermatitis: A pragmatic approach. Clin Exp Dermatol 2000;25:261-264.
39. Dooms-Goossens AE, Degreef HJ, Marien KJ, Coopman SA: Contact allergy to corticosteroids: A frequently missed diagnosis? J Am Acad Dermatol 1998;21:538-543.
40. Wilkinson SM, Jones MF: Corticosteroid usage and binding to arginine: Determinants of corticosteroid hypersensitivity. Br J Dermatol 1996;135:225-230.
41. Wilkinson SM, Beck MH: Fluticasone propionate and mometasone furoate have a low risk of contact sensitization. Contact Dermatitis 1996;34:365-366.
42. Goossens A, Huygens S, Matura M, Degreef H: Fluticasone propionate: A rare contact sensitizer. Eur J Dermatol 2001;11:29-34.
43. Venning VA: Fluticasone propionate sensitivity in a patient with contact allergy to multiple corticosteroids. Contact Dermatitis 1995;33:48-49.
44. Lebwohl M: Efficacy and safety of fluticasone propionate ointment, 0.005%, in the treatment of eczema. Cutis 1996;57:62-68.
45. Delescluse J, van der Endt JD: A comparison of the safety, tolerability, and efficacy of fluticasone propionate ointment, 0.005%, and betamethasone-17,21-dipropionate ointment, 0.05%, in the treatment of eczema. Cutis 1996;57:32-38.
46. Tan MH, Meador SL, Singer G, Lebwohl MG: An open-label study of the safety and efficacy of limited application of fluticasone propionate ointment, 0.005%, in patients with atopic dermatitis of the face and intertriginous areas. Int J Dermatol 2002;41:804-809.
47. Meurer M, Fölster-Holst R, Wozel G, Weidinger G, Jünger M, Bräutigam M, CASM-DE-01 Study Group: Pimecrolimus cream in the longterm management of atopic dermatitis in adults: A six-month study. Dermatology 2002;205:271-277.
48. Lucky AW, Leach AD, Laskarzewski P, Wenck H: Use of an emollient as a steroid-sparing agent in the treatment of mild to moderate atopic dermatitis in children. Pediatr Dermatol 1997;14:321-324.
49. Boner AL, Richelli C, De Stefano G, Valletta EA, Ferrari S, Mengoni M: Hypothalamic-pituitary-adrenal function in children with atopic dermatitis treated with clobetasone butyrate and its clinical evaluation. Int J Pharmacol Ther Toxicol 1985;23:118-120.
50. Wolkerstorfer A, Strobos MA, Glazenburg EJ, Mulder PG, Oranje AP: Fluticasone propionate 0.05% cream once daily versus clobetasone butyrate 0.05% cream twice daily in children with atopic dermatitis. J Am Acad Dermatol 1998;39:226-231.
51. Bridgman A: The use of wet-wrap dressings for eczema. Paediatr Nurs 1995;7:24-27.
52. Pei AY, Chan HH, Ho KM: The effectiveness of wet wrap dressings using 0.1% mometasone furoate and 0.005% fluticasone propionate ointments in the treatment of moderate to severe atopic dermatitis in children. Pediatr Dermatol 2001;18:343-348.
53. Wolkerstorfer A, Visser RL, De Waard van der Spek FB, Mulder PG, Oranje AP: Efficacy and safety of wet-wrap dressings in children with severe atopic dermatitis: Influence of corticosteroid dilution. Br J Dermatol 2000;143:999-1004.
54. Przybilla B, Eberlein-König B, Rueff F: Practical management of atopic eczema. Lancet 1994;343:1342-1346.
55. Van Der Meer JB, Glazenburg EJ, Mulder PG, Eggink HF, Coenraads PJ: The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. Br J Dermatol 1999;140:1114-1121.
56. Hanifin J, Gupta AK, Rajagopalan R: Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002;147:528-537.
57. Berth-Jones J, Damstra RJ, Golsch S, Livden JK, Van Hooteghem O, Allegra F, Parker CA, Multinational Study Group: Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: Randomised, double blind, parallel group study. BMJ 2003;326:1367-1373.
58. Kirkup ME, Birchall NM, Weinberg EG, Helm K, Kennedy CT: Acute and maintenance treatment of atopic dermatitis in children - Two comparative studies with fluticasone propionate (0.05%) cream. J Dermatol Treat 2003;14:141-148.
59. Callen J: Comparison of safety and efficacy of fluticasone propionate cream, 0.05%, and betamethasone valerate cream, 0.1%, in the treatment of moderate-to-severe psoriasis. Cutis 1996;57:45-50.
60. James M: A randomized, double-blind, multicenter trial comparing fluticasone propionate cream, 0.1%, applied twice daily for 4 weeks in the treatment of psoriasis. Cutis 1996;67:2-9.
61. Nürnberger FG: A comparison of fluticasone propionate ointment, 0.005%, and hydrocortisone-17-butyrate ointment, 0.1%, in the treatment of psoriasis. Cutis 1996;57:39-44.
62. Roberts DT: Comparison of fluticasone propionate ointment, 0.005%, and betamethasone-17,21-dipropionate ointment, 0.05%, in the treatment of psoriasis. Cutis 1996;57:27-31.
63. Lebwohl MG, Tan MH, Meador SL, Singer G: Limited application of fluticasone propionate ointment, 0.005% on patients with psoriasis of the face and intertriginous areas. J Am Acad Dermatol 2001;44:77-82.
64. Liu XQ, Shao CG, Jin PY, Wang HQ, Ye GY, Yawalkar S: Treatment of localized vitiligo with ulobetasol cream. Int J Dermatol 1990;29:295-297.
65. Westerhof W, Nieuweboer-Krobotova L, Mulder PG, Glazenburg EJ: Left-right comparison study of the combination of fluticasone propionate and UV-A vs either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo. Arch Dermatol 1999;135:1061-1066.
66. Hachem JP, De Paepe K, Vanpee E, Bogaerts M, Kaufman L, Rogiers V, Roseeuw D: Efficacy of topical corticosteroids in nickel-induced contact allergy. Clin Exp Dermatol 2002;27:47-50.
67. Hachem JP, De Paepe K, Vanpee E, Kaufman L, Rogiers V, Roseeuw D: Combination therapy improves the recovery of the skin barrier function: An experimental model using a contact allergy patch test combined with TEWL measurements. Dermatology 2001;202:314-319.
68. Elsner P, Kerscher M, Korting HC, Krutmann J, Luger TA, Niedner R, Röcken M, Ruzicka T, Kapp A, Schwarz T: Topische Dermatotherapie mit Glukokortikoiden - Therapeutischer Index. AWMF online 2003;www.awmf-leitlinien. de: AWMF-Reg.-Nr. 013/034.